دورية أكاديمية
A-448 - Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)
| العنوان: | A-448 - Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM) |
|---|---|
| المؤلفون: | Burton, E., Honaker, V., Milton, D., Glitza, I., Amaria, R., Patel, S., Diab, A., Wong, M., McQuade, J., Chung, C., Wefel, J., Li, J., Davies, M., Tawbi, H. |
| المصدر: | In EJC Skin Cancer 2024 2 Supplement 1 |
| قاعدة البيانات: | ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 27726118 |
|---|---|
| DOI: | 10.1016/j.ejcskn.2024.100160 |